Do all critically ill patients with covid-19 disease benefit from adding tocilizumab to glucocorticoids? a retrospective cohort study

HIGHLIGHTS

  • who: Cristina Mussini and collaborators from the Department of Infectious Diseases, Azienda Ospedaliero-Universitaria Policlinico of Modena, Modena, Italy Department of Surgical, Medical, Dental and Morphological Sciences University of Modena and Reggio have published the research: Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study, in the Journal: (JOURNAL) of June/16,/2020
  • what: The authors aimed to estimate the causal effect of + tocilizumab on mortality overall and after stratification for PaO2 /FiO2 ratio and CRP levels. The study showed higher effectiveness of tocilizumab when . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?